In general, most immune checkpoints (including PD-1, TIM-3, CD96, PDCD1, IDO1, PDCD1LG2, and CTLA-4) were highly expressed in glioma cells (39–42). This evidence concerns the gene PDCD1LG2 and central nervous system cancer.